Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/2876/9/16: Health professional v AbbVie (Humira) – β€˜Fast symptom relief’ claim in journal ad (No breach)

A health professional challenged AbbVie’s Humira ad claim β€œFast symptom relief from week 1 (CD) and week 2…

8 Mar 2026

AUTH/2961/6/17: Indivior v Martindale β€” Espranor website promoted to the public and β€œno diversion/instant disintegration” claims ruled misleading

Martindale’s Espranor launch materials (open website, detail aids, patient leaflet) were ruled to promote a POM to the…

8 Mar 2026

AUTH/1967/2/07: PCT prescribing lead v Novartis β€” alleged claim that Exforge was PCT-endorsed (No breach)

A PCT complained a Novartis rep said Exforge was endorsed by the PCT. Evidence suggested a misunderstanding between…

8 Mar 2026

AUTH/2967/8/17 – Consultant v Shire: Omission of prescribing information and other obligatory information (No breach / Out of scope)

PMCPA case AUTH/2967/8/17 (Consultant v Shire). Allegation: omission of prescribing and obligatory information. Outcome: no breach; matter found…

8 Mar 2026

Sanofi-Aventis & Bristol-Myers Squibb: MINAP meeting invitation misleadingly implied endorsement (AUTH/2029/7/07, AUTH/2030/7/07)

MINAP complained a sponsored meeting invite implied MINAP Steering Committee involvement/endorsement. Panel found the invitation misleading and not…

8 Mar 2026

AUTH/2354/9/10: Anonymous v Consilient Health β€” Promotion of oral contraceptives (out of scope; no breach)

PMCPA case AUTH/2354/9/10 (Anonymous v Consilient Health) about promotion of oral contraceptives. The matter was ruled outwith the…

8 Mar 2026

Napp: Invokana renal outcomes discussion at conference stand; internal CREDENCE training slides ruled to breach

Anonymous pharmacist alleged off-licence CKD promotion of Invokana at a diabetes conference. Panel couldn’t prove what was said…

8 Mar 2026

Roche and Chugai: complaint about allegedly out-of-date RoActemra prescribing information (no breach)

A UK health professional alleged RoActemra prescribing information in a Guidelines in Practice product review was out of…

8 Mar 2026

Novartis breached ABPI Code after edited Beovu HCP video omitted safety caution (AUTH/3464/1/21)

PMCPA ruled Novartis’ edited Beovu β€œfirst experience” HCP video was misleading because it retained positive case outcomes but…

8 Mar 2026

UCB: Employee β€˜liked’ LinkedIn post about Bimzelx, ruled promotion of a POM to the public (AUTH/3554/8/21)

A UCB employee β€˜liked’ a third-party LinkedIn post about Bimzelx EU approval. The Panel said a β€˜like’ can…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training